326 related articles for article (PubMed ID: 21968238)
1. Long-term remission of ocular and extraocular manifestations in Behçet's disease using infliximab.
Handa T; Tsunekawa H; Yoneda M; Watanabe D; Mukai T; Yamamura M; Iwaki M; Zako M
Clin Exp Rheumatol; 2011; 29(4 Suppl 67):S58-63. PubMed ID: 21968238
[TBL] [Abstract][Full Text] [Related]
2. Infliximab treatment for ocular and extraocular manifestations of Behçet's disease.
Accorinti M; Pirraglia MP; Paroli MP; Priori R; Conti F; Pivetti-Pezzi P
Jpn J Ophthalmol; 2007; 51(3):191-6. PubMed ID: 17554481
[TBL] [Abstract][Full Text] [Related]
3. Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study.
Niccoli L; Nannini C; Benucci M; Chindamo D; Cassarà E; Salvarani C; Cimino L; Gini G; Lenzetti I; Cantini F
Rheumatology (Oxford); 2007 Jul; 46(7):1161-4. PubMed ID: 17478466
[TBL] [Abstract][Full Text] [Related]
4. Infliximab in the treatment of posterior uveitis in Behçet's disease. Long term follow up in four patients.
Lanthier N; Parc C; Scavennec R; Dhôte R; Brézin AP; Guillevin L
Presse Med; 2005 Jul; 34(13):916-8. PubMed ID: 16142147
[TBL] [Abstract][Full Text] [Related]
5. Adalimumab for treatment of severe Behçet's uveitis: a retrospective long-term follow-up study.
Interlandi E; Leccese P; Olivieri I; Latanza L
Clin Exp Rheumatol; 2014; 32(4 Suppl 84):S58-62. PubMed ID: 25005224
[TBL] [Abstract][Full Text] [Related]
6. Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Behçet's disease.
Abu El-Asrar AM; Abboud EB; Aldibhi H; Al-Arfaj A
Int Ophthalmol; 2005 Jun; 26(3):83-92. PubMed ID: 17031510
[TBL] [Abstract][Full Text] [Related]
7. Long-term clinical outcomes in patients with refractory uveitis associated with Behçet disease treated with infliximab.
Al Rashidi S; Al Fawaz A; Kangave D; Abu El-Asrar AM
Ocul Immunol Inflamm; 2013 Dec; 21(6):468-74. PubMed ID: 23734940
[TBL] [Abstract][Full Text] [Related]
8. Effects of infliximab in the treatment of refractory posterior uveitis of Behçet's disease after withdrawal of infusions.
Adán A; Hernandez V; Ortiz S; Molina JJ; Pelegrin L; Espinosa G; Sanmartí R
Int Ophthalmol; 2010 Oct; 30(5):577-81. PubMed ID: 20490893
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behçet's disease: a multicenter study.
Takeuchi M; Kezuka T; Sugita S; Keino H; Namba K; Kaburaki T; Maruyama K; Nakai K; Hijioka K; Shibuya E; Komae K; Hori J; Ohguro N; Sonoda KH; Mizuki N; Okada AA; Ishibashi T; Goto H; Mochizuki M
Ophthalmology; 2014 Oct; 121(10):1877-84. PubMed ID: 24950593
[TBL] [Abstract][Full Text] [Related]
10. The efficacy of a single dose of infliximab in the treatment of Behçet's disease uveitis.
Arayssi T; Hamra R; Homeidan F; Uthman I; Awwad ST; Mroue K; Mansour W; Bashshur ZF
Clin Exp Rheumatol; 2005; 23(3):427. PubMed ID: 15971438
[No Abstract] [Full Text] [Related]
11. MONTHLY INTRAVITREAL INFLIXIMAB IN BEHÇET'S DISEASE ACTIVE POSTERIOR UVEITIS: A Long-Term Safety Study.
Refaat M; Abdullatif AM; Hamza MM; Macky TA; El-Agha MH; Ragab G; Soliman MM
Retina; 2021 Aug; 41(8):1739-1747. PubMed ID: 33394998
[TBL] [Abstract][Full Text] [Related]
12. Health- and vision-related quality of life in patients receiving infliximab therapy for Behcet uveitis.
Sakai T; Watanabe H; Kuroyanagi K; Akiyama G; Okano K; Kohno H; Tsuneoka H
Br J Ophthalmol; 2013 Mar; 97(3):338-42. PubMed ID: 23314623
[TBL] [Abstract][Full Text] [Related]
13. Anti-TNF-alpha therapy in seven patients with Behcet's uveitis: advantages and controversial aspects.
Tognon S; Graziani G; Marcolongo R
Ann N Y Acad Sci; 2007 Sep; 1110():474-84. PubMed ID: 17911463
[TBL] [Abstract][Full Text] [Related]
14. Induction of regulatory T cells by infliximab in Behcet's disease.
Sugita S; Yamada Y; Kaneko S; Horie S; Mochizuki M
Invest Ophthalmol Vis Sci; 2011 Jan; 52(1):476-84. PubMed ID: 20861484
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial.
Tugal-Tutkun I; Mudun A; Urgancioglu M; Kamali S; Kasapoglu E; Inanc M; Gül A
Arthritis Rheum; 2005 Aug; 52(8):2478-84. PubMed ID: 16052571
[TBL] [Abstract][Full Text] [Related]
16. Anti-TNF-alpha therapy for sight threatening uveitis.
Lindstedt EW; Baarsma GS; Kuijpers RW; van Hagen PM
Br J Ophthalmol; 2005 May; 89(5):533-6. PubMed ID: 15834077
[TBL] [Abstract][Full Text] [Related]
17. Methotrexate in ocular manifestations of Behcet's disease: a longitudinal study up to 15 years.
Davatchi F; Shams H; Shahram F; Nadji A; Chams-Davatchi C; Sadeghi Abdollahi B; Faezi T; Akhlaghi M; Ashofteh F
Int J Rheum Dis; 2013 Oct; 16(5):568-77. PubMed ID: 24164845
[TBL] [Abstract][Full Text] [Related]
18. Infliximab for the treatment of resistant oral ulcers in Behçet's disease: a case report and review of the literature.
Almoznino G; Ben-Chetrit E
Clin Exp Rheumatol; 2007; 25(4 Suppl 45):S99-102. PubMed ID: 17949561
[TBL] [Abstract][Full Text] [Related]
19. Infliximab monotherapy versus infliximab and colchicine combination therapy in patients with Behçet's disease.
Takeuchi M; Asukata Y; Kawagoe T; Ito N; Nishide T; Mizuki N
Ocul Immunol Inflamm; 2012 Jun; 20(3):193-7. PubMed ID: 22486264
[TBL] [Abstract][Full Text] [Related]
20. Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behcet's disease on infliximab therapy.
Keino H; Okada AA; Watanabe T; Taki W
Br J Ophthalmol; 2011 Sep; 95(9):1245-50. PubMed ID: 21183514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
